- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07609381
Clinical Information System Impact on Hospitalized Patients With Chronic Disease
Evaluating the Impact of Alberta Health Services' New Provincial Clinical Information System on Patient Outcomes and Experiences With Chronic Diseases - Study Protocol for a Multi-center Interrupted Time Series Analysis
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
The design of the protocol is a multiple-baseline interrupted time series (ITS) analysis to assess effects of the CIS on patient outcomes with five pre-specified NCDs (diabetes mellitus, coronary artery disease, heart failure, chronic kidney disease, and chronic lung disease) before versus after implementation at each cluster of sites, accounting for pre-existing trends in outcomes and correlation between different time points and sites. The primary outcome will be unplanned hospital readmission and death within 30 days of discharge. Secondary outcomes will include readmission and death as individual outcomes, length of hospital stay, processes of care, and measures of patient experience with care transitions.
The study uses retrospective administrative, clinical, and patient experience data collected between 2019 and 2024, covering periods before and after clinical information system implementation at each site. All observations will be recorded prior to study initiation and will be analyzed retrospectively within a multiple baseline interrupted time series framework.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Nusrat S Shommu, PhD
- Telefoonnummer: 4032103991
- E-mail: nsshommu@ucalgary.ca
Studie Locaties
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N1
- University Of Calgary
-
Contact:
- Nusrat S Shommu, PhD
- Telefoonnummer: 4032103991
- E-mail: nsshommu@ucalgary.ca
-
Hoofdonderzoeker:
- Matthew T James, MD, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Adults aged 18 years or older at the time of hospital admission.
- Residents of Alberta eligible to receive acute-care services in AHS facilities.
- Hospitalized for any cause during the study period (5 years pre-implementation and 2 years post-implementation of the CIS).
- Meet the validated case definition for one or more of the five key NCDs (diabetes mellitus, chronic kidney disease, coronary artery disease, heart failure, or chronic lung disease) based on ICD codes, laboratory measures, or pharmacy records during standardized lookback periods (up to 5 years for diagnoses; up to 1 year for labs/pharmacy).
- Have a qualifying date for the NCD(s) that occurs prior to or during the index hospital admission.
- Eligible for inclusion in the primary and patient experience outcomes if they survive to hospital discharge.
- May enter multiple sub-cohorts if more than one NCD is present.
Exclusion Criteria:
- Individuals younger than 18 years at the time of hospital admission.
- Non-residents of Alberta or individuals not eligible for care within AHS facilities.
- Hospitalizations that end in death (excluded from analyses of the primary outcome and patient experience measures).
- Patients without evidence of any of the five key NCDs during the lookback period or at the index hospital admission.
- Admissions outside the study period or admissions for which necessary administrative, laboratory, or pharmacy data are unavailable.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Adults with Key NCDs Receiving Acute Care in AHS
This single cohort includes adult patients in Alberta with one of five key noncommunicable diseases (diabetes mellitus, chronic kidney disease, coronary artery disease, heart failure, or chronic lung disease) who received care in Alberta Health Services (AHS) acute-care facilities during the study period.
The cohort is followed over a 7-year window (5 years pre-implementation and 2 years post-implementation of the Clinical Information System), with outcomes measured in into quarterly intervals, both pre- and post-launch of the CIS at each site for this analysis.
Sub-cohorts will be identified based on the presence of each NCD and hospitalization history, but all belong to one predefined observational study cohort for the interrupted time series analysis.
|
The intervention (exposure) is the implementation of the Connect Care Clinical Information System (CIS) across Alberta Health Services (AHS) acute-care facilities.
Connect Care integrates comprehensive electronic health records, clinician communication tools, pharmacy dispensing data, laboratory and diagnostic imaging results, standardized medication reconciliation, and electronic discharge summaries.
It supports coordination across hospital, specialty, and primary care settings and includes a patient-facing portal allowing access to personal health information.
The CIS rollout occurred at multiple sites with staggered launch dates and represents one of the largest Epic deployments.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
All-cause unplanned hospital readmission or death within 30 days after hospital discharge
Tijdsspanne: Within 30 days after hospital discharge
|
This primary outcome captures whether a patient experiences either (1) the unplanned hospital readmission for any cause or (2) death from any cause within 30 days following discharge from an acute-care hospitalization.
The outcome is restricted to patients who survived to hospital discharge.
Analyses will also be stratified by the presence of each of the five key NCDs (diabetes, CKD, CAD, heart failure, chronic lung disease) and by multimorbidity (two or more of the NCDs).
|
Within 30 days after hospital discharge
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Acute care admission frequency
Tijdsspanne: Monthly intervals across the 7-year follow-up (5 years pre-implementation, 2 years post-implementation
|
Number of acute-care hospital admissions occurring during monthly intervals.
|
Monthly intervals across the 7-year follow-up (5 years pre-implementation, 2 years post-implementation
|
|
Length of stay in hospital
Tijdsspanne: From hospital admission date to date of discharge or switch to alternate level of care, up to a maximum of 30 days
|
Duration of index hospitalization in days, excluding days coded as alternate level of care (occupying a hospital bed but no longer needing acute care while waiting for a transfer to a more suitable setting like long-term care, rehab, or home support), measured from admission to discharge, including multi-facility episodes.
|
From hospital admission date to date of discharge or switch to alternate level of care, up to a maximum of 30 days
|
|
30-day all-cause mortality
Tijdsspanne: Within 30 days after each discharge.
|
Death from any cause within 30 days after hospital discharge, assessed independently from readmission.
|
Within 30 days after each discharge.
|
|
30-day all-cause readmission
Tijdsspanne: Within 30 days after each discharge.
|
Any acute-care readmission occurring within 30 days after discharge, analyzed separately from mortality.
|
Within 30 days after each discharge.
|
|
Emergency department visits within 30 days of discharge
Tijdsspanne: Within 30 days after each discharge.
|
Count of emergency department visits within 30 days following discharge.
|
Within 30 days after each discharge.
|
|
Outpatient physician follow-up within 30 days
Tijdsspanne: Within 30 days after each discharge.
|
Completion of a primary care or specialist outpatient visit within 30 days after discharge (restricted to patients who survived to discharge).
|
Within 30 days after each discharge.
|
|
Medication dispensation within 120 days of discharge
Tijdsspanne: Within 120 days after discharge.
|
ACE-I/ARB/ARNI prescription dispensed within 120 days for patients with heart failure, CAD, or CKD with ACR >30 mg/mmol.Statin prescription dispensed within 120 days for patients with ASCVD, diabetes (age >40 years), or CKD (age >50 years).
|
Within 120 days after discharge.
|
|
Outpatient laboratory testing within 30 days of discharge
Tijdsspanne: Within 30 days after each discharge.
|
Completion of recommended outpatient laboratory testing during the early post-discharge period (restricted to patients who survived to discharge).
|
Within 30 days after each discharge.
|
|
Multi-question composite score of Information Understanding When Leaving the Hospital from the Canadian Patient Experiences Survey on Inpatient Care
Tijdsspanne: Survey completed up to12 weeks following discharge among a 10% random sample of patients discharged.
|
Composite score based on three questions related to Information Understanding When Leaving the Hospital
|
Survey completed up to12 weeks following discharge among a 10% random sample of patients discharged.
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Interrupted time series (ITS) slope and level changes
Tijdsspanne: Monthly intervals for 5 years pre-implementation and 2 years post-implementation.
|
Estimated changes in outcome level and trend immediately following CIS implementation and over time, using monthly segmented regression across staggered site launch dates.
|
Monthly intervals for 5 years pre-implementation and 2 years post-implementation.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Matthew T James, MD, PhD, University Of Calgary
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Endocriene systeemziekten
- Vaatziekten
- Hart-en vaatziekten
- Mannelijke urogenitale ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Hartziekten
- Metabole ziekten
- Glucosemetabolismestoornissen
- Arteriosclerose
- Arteriële occlusieve ziekten
- Hart-en vaatziekte
- Myocardiale ischemie
- Voedings- en stofwisselingsziekten
- Hartfalen
- Suikerziekte
- Coronaire hartziekte
- Nier Ziekten
- Organisatie en administratie
- Health Services Administration
- Management Information Systems
- cytokine inducible SH2-containing protein
Andere studie-ID-nummers
- REB24-1942
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .